Axion’s MEA systems can model complex brain activity and heartbeats in a dish. As a result, toxicity and efficacy can be assessed earlier in the drug development process, and with greater sensitivity and accuracy. These comprehensive system-level evaluations provide an in vitro solution to reducing animal testing, a key objective of the Tox21 and REACH initiatives.
Axion’s MEA systems provide a label-free in vitro platform for direct measurement of electrical activity in neurons and cardiomyocytes, while the efficiency and convenience of Axion’s standard MEA plates facilitate use for screening-level applications. The large number of electrodes per well reveals detailed information about systems-level signal propogation.
Axion’s Maestro highlighted in Charles River Labs’ cardiac safety testing portfolio
Visit Charles River Labs’ recent blog post detailing the proposed CiPA initiative. In the spotlight: incorporation of an iPSC cardiomyocyte assay run on the Maestro platform.
View the post
MEA: After Dark – Cambridge, MA
Axion BioSystems invites you to join us on the Harvard University campus Tuesday evening, April 28th from 5:30-7:30pm to learn about using Microelectrode Arrays (MEA) for modeling neurological diseases in vitro.
•Happy Hour refreshments
•Introduction to MEA and the Maestro platform
•Overview of AxIS acquisition and analysis software including training on the Neural Metric tool for comprehensive neural data analysis
•Advanced Q&A for existing users
Sherman Fairchild Bldg; Room 268
Space is limited; register today!